In a patient with a normal‑sized left ventricle, mildly increased wall thickness, moderate septal thickening, moderately increased ventricular mass, reduced ejection fraction of 40‑45 %, and grade I diastolic dysfunction, what are the recommended next steps in management?

Management Recommendations for Reduced EF with LV Hypertrophy

The immediate priority is to exclude hypertrophic cardiomyopathy (HCM) and infiltrative cardiomyopathies (particularly cardiac amyloidosis), as these require fundamentally different treatment strategies than standard heart failure therapy and significantly impact prognosis.

Critical Diagnostic Workup Required

This echocardiogram reveals a concerning pattern: reduced ejection fraction (40-45%) combined with increased wall thickness and septal hypertrophy—a combination that demands investigation for specific etiologies before initiating standard heart failure treatment.

Rule Out HCM and Infiltrative Disease

The 2024 AHA/ACC HCM guidelines 1 define HCM as maximal end-diastolic wall thickness ≥15 mm, but note that "more limited hypertrophy (13-14 mm) can be diagnostic when present in family members of a patient with HCM or in conjunction with a positive genetic test." Your patient has moderate septal thickening with moderately increased ventricular mass—this warrants:

1. Obtain detailed family history specifically for:

   • Sudden cardiac death in relatives <50 years
   • Known HCM in family members
   • Unexplained heart failure in relatives

2. Cardiac MRI with late gadolinium enhancement is essential to:

   • Precisely quantify wall thickness and distribution
   • Detect patterns of fibrosis characteristic of HCM (mid-wall enhancement)
   • Identify infiltrative processes (amyloidosis shows diffuse subendocardial enhancement)
   • Rule out apical aneurysms or atypical hypertrophy patterns 2

3. Screen for infiltrative cardiomyopathies, particularly given the reduced EF with hypertrophy:

   • Serum and urine protein electrophoresis with immunofixation (light chain amyloidosis)
   • Nuclear scintigraphy with technetium-99m pyrophosphate (ATTR amyloidosis)
   • Consider endomyocardial biopsy if non-invasive testing is inconclusive

The case report 3 illustrates why this matters: an 83-year-old with HFrEF (EF 22%) and ATTRwt cardiac amyloidosis had LV wall thickness of only 11.3 mm initially—demonstrating that infiltrative disease can present with reduced EF before marked hypertrophy develops. Disease-modifying therapies for amyloidosis (tafamidis, patisiran) are now available and fundamentally alter outcomes.

Assess for Secondary Causes of LVH

Before attributing findings to primary cardiomyopathy:

• Blood pressure assessment: Obtain ambulatory BP monitoring if hypertension history is unclear—hypertensive cardiomyopathy can produce similar morphology 1
• Aortic valve evaluation: The report notes "valve structure is normal, no stenosis," but confirm peak velocity <2.5 m/s to definitively exclude mild stenosis
• Coronary evaluation: Given reduced EF with normal wall motion (unusual), consider stress testing or coronary angiography to exclude ischemic cardiomyopathy with balanced ischemia

If HCM and Infiltrative Disease Are Excluded

Evaluate for Dynamic LVOT Obstruction

The 2024 guidelines 2 emphasize that up to 50% of patients with obstructive physiology are missed on resting echocardiography. Your patient has septal hypertrophy—repeat echocardiography with:

• Provocative maneuvers: Valsalva, squat-to-stand, or standing
• Exercise echocardiography if symptoms are effort-related and resting gradient <50 mmHg
• Document peak LVOT gradient; if ≥50 mmHg, this fundamentally changes management (avoid afterload reducers, consider septal reduction therapy)

Standard Heart Failure Management

If no specific etiology is identified, initiate guideline-directed medical therapy for HFrEF:

1. Neurohormonal blockade:

   • ACE inhibitor or ARB (titrate to target doses)
   • Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
   • Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
   • SGLT2 inhibitor (dapagliflozin or empagliflozin)

2. Diuretics for volume management: The grade I diastolic dysfunction and trace valvular regurgitation suggest relatively preserved filling pressures, but titrate loop diuretics to symptoms

3. Serial monitoring: Repeat echocardiography in 3-6 months to assess for:

   • EF improvement (reverse remodeling)
   • Progression of wall thickness (suggests infiltrative process)
   • Development of LVOT obstruction

Critical Pitfalls to Avoid

Do not assume this is simple HFrEF with hypertensive heart disease. The combination of reduced EF with increased wall thickness is atypical—most HFrEF patients have dilated, thin-walled ventricles. The research evidence 4 shows that septal hypertrophy in HFmrEF (EF 41-49%) predicts HF rehospitalization, and your patient's EF is even lower.

Do not start standard vasodilators if LVOT obstruction is present—this can precipitate hemodynamic collapse. The guidelines 2 specify that provocative maneuvers are essential before attributing symptoms to obstruction.

Do not delay cardiac MRI—it provides definitive characterization that echocardiography cannot match, particularly for infiltrative disease and precise wall thickness quantification 2.

Immediate Next Steps Algorithm

1. Order cardiac MRI with LGE (within 2-4 weeks)
2. Screen for amyloidosis (serum/urine studies, nuclear scan)
3. Obtain detailed family history and consider genetic testing if HCM suspected
4. Repeat echo with provocative maneuvers to assess LVOT gradient
5. Hold standard HF therapy until specific diagnosis clarified, unless patient is symptomatic (then cautiously initiate beta-blocker and diuretics only)
6. Refer to advanced heart failure/cardiomyopathy specialist for definitive diagnosis and management planning

The diastolic dysfunction 5, 6 is an important prognostic marker but does not change immediate management—addressing the underlying etiology of the reduced EF with hypertrophy is paramount.